CVE:RX BioSyent (RX) Stock Price, News & Analysis C$12.10 +0.05 (+0.41%) As of 08/27/2025 10:07 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesInsider TradesBuy This Stock About BioSyent Stock (CVE:RX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioSyent alerts:Sign Up Key Stats Today's RangeC$12.00▼C$12.1050-Day RangeC$11.15▼C$12.1052-Week RangeC$9.20▼C$12.40Volume5,950 shsAverage Volume4,137 shsMarket CapitalizationC$138.39 millionP/E Ratio19.64Dividend Yield1.49%Price TargetN/AConsensus RatingN/A Company Overview BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada. Read More Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RX Stock News HeadlinesFY2025 Earnings Forecast for BioSyent Issued By Bloom Burton4 hours ago | americanbankingnews.comBioSyent (CVE:RX) Reaches New 1-Year High After Dividend AnnouncementAugust 24, 2025 | americanbankingnews.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world. | Traders Agency (Ad)BioSyent Declares Consistent Q3 2025 DividendAugust 22, 2025 | msn.comBioSyent Inc. Reports Robust Growth in Q2 and H1 2025 Financial ResultsAugust 22, 2025 | msn.comBioSyent Declares Third Quarter 2025 DividendAugust 21, 2025 | financialpost.comFBioSyent Releases Financial Results for Q2 and H1 2025August 21, 2025 | financialpost.comFBioSyent to Announce Q2 and H1 2025 Financial ResultsAugust 14, 2025 | msn.comSee More Headlines RX Stock Analysis - Frequently Asked Questions How have RX shares performed this year? BioSyent's stock was trading at C$11.00 at the beginning of the year. Since then, RX stock has increased by 10.0% and is now trading at C$12.10. How were BioSyent's earnings last quarter? BioSyent Inc. (CVE:RX) announced its quarterly earnings results on Thursday, May, 25th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The firm had revenue of $3.82 million for the quarter, compared to analysts' expectations of $4.80 million. BioSyent had a trailing twelve-month return on equity of 20.01% and a net margin of 20.60%. How do I buy shares of BioSyent? Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of BioSyent own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Astec Industries (ASTE), Bank of Nova Scotia (BNS), Carnival (CCL), Cisco Systems (CSCO), Devon Energy (DVN) and Ford Motor (F). Company Calendar Last Earnings5/25/2017Today8/27/2025Record date for 9/15 Dividend8/29/2025Dividend Payable9/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:RX CIKN/A Webwww.biosyent.com Phone+1-905-2060013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C$0.62 Trailing P/E Ratio19.64 Forward P/E Ratio17.42 P/E GrowthN/ANet IncomeC$7.02 million Net Margins20.60% Pretax MarginN/A Return on Equity20.01% Return on Assets12.86% Debt Debt-to-Equity Ratio2.90 Current Ratio3.92 Quick Ratio6.91 Sales & Book Value Annual SalesC$34.06 million Price / Sales4.06 Cash FlowC$3.94 per share Price / Cash Flow3.07 Book ValueC$3.22 per share Price / Book3.75Miscellaneous Outstanding Shares11,437,447Free FloatN/AMarket CapC$138.39 million OptionableNot Optionable Beta0.93 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (CVE:RX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.